As BRAF program moves forward, Fore turns to insiders for more series D cash

SR One, Medicxi and Orbimed were among Fore’s deep bench of existing investors that refueled the Philadelphia-based biotech this week with a $38 million series D-2 financing as it continues its pursuit of a better BRAF.

“We’re really well-situated,” William Hinshaw told BioCentury, speaking of the group of VC backers that attracted him to Fore Biotherapeutics Inc.’s CEO job in early 2024 to advance plixorafenib, an oral small molecule that selectively inhibits mutated BRAF. Other participants in the financing included HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management and 3B Future Health Fund. ...